StreetInsider.com News Articles

CSL names Deborah Waterhouse as CEO, effective February 2027

Wed, 21 Oct 2026 03:54:17 -0400

CSL Limited (ASX: CSL; USOTC: CSLLY) has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director, effective February 1, 2027, following a global search process conducted by the company's board of directors.

Waterhouse, 25-plus years in the pharmaceutical industry, has served as CEO of ViiV Healthcare since 2017. ViiV Healthcare is a joint venture majority owned by GSK, with Shionogi as a shareholder, specializing in HIV treatments. The business reported sales of £7.7 billion in GSK's 2025 financial year. Waterhouse also holds the title of President of GSK Global Health.

Her previous roles at GSK include leading the company's U.S. vaccines

CSL names Deborah Waterhouse as CEO, effective February 2027

Wed, 21 Oct 2026 03:54:17 -0400

Her previous roles at GSK include leading the company's U.S. vaccines

CSL appoints Deborah Waterhouse as CEO & Managing Director

Wed, 21 Oct 2026 03:53:00 -0400

MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors.

Ms Waterhouse is

CSL appoints Deborah Waterhouse as CEO & Managing Director

Wed, 21 Oct 2026 03:53:00 -0400

Ms Waterhouse is

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Sun, 04 Oct 2026 17:42:00 -0400

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared

MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Sun, 04 Oct 2026 17:42:00 -0400

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

Tue, 29 Sep 2026 09:30:00 -0400

HOLLY SPRINGS, N.C., Sept. 29, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing campaign.

With the majority of customer orders already shipped and deliveries expected to be completed ahead of schedule,

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

Tue, 29 Sep 2026 09:30:00 -0400

With the majority of customer orders already shipped and deliveries expected to be completed ahead of schedule,

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD182.50 at Goldman Sachs

Mon, 28 Sep 2026 02:24:15 -0400

Goldman Sachs analyst Davin Thillainathan raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD182.50 (from AUD163.60) while maintaining a Buy rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD182.50 at Goldman Sachs

Mon, 28 Sep 2026 02:24:15 -0400

Goldman Sachs analyst Davin Thillainathan raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD182.50 (from AUD163.60) while maintaining a Buy rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD182.50 at Goldman Sachs

Mon, 28 Sep 2026 02:24:15 -0400

Goldman Sachs analyst Davin Thillainathan raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD182.50 (from AUD163.60) while maintaining a Buy rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD182.50 at Goldman Sachs

Mon, 28 Sep 2026 02:24:15 -0400

Goldman Sachs analyst Davin Thillainathan raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD182.50 (from AUD163.60) while maintaining a Buy rating.

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Thu, 10 Sep 2026 18:40:00 -0400

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.

MAIDENHEAD, United Kingdom, Sept. 10, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59^®-adjuvanted

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Thu, 10 Sep 2026 18:40:00 -0400

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD160 at Citi

Thu, 20 Aug 2026 07:24:27 -0400

Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD160 at Citi

Thu, 20 Aug 2026 07:24:27 -0400

Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD160 at Citi

Thu, 20 Aug 2026 07:24:27 -0400

Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD160 at Citi

Thu, 20 Aug 2026 07:24:27 -0400

Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD181 at UBS

Wed, 19 Aug 2026 03:21:33 -0400

UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD181 at UBS

Wed, 19 Aug 2026 03:21:33 -0400

UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD181 at UBS

Wed, 19 Aug 2026 03:21:33 -0400

UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating.

CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD181 at UBS

Wed, 19 Aug 2026 03:21:33 -0400

UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating.

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

Mon, 27 Jul 2026 09:00:00 -0400

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year
Full data to be presented at upcoming scientific congress

KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is approved in over 40 countries for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

Mon, 27 Jul 2026 09:00:00 -0400

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year
Full data to be presented at upcoming scientific congress

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

Mon, 27 Jul 2026 09:00:00 -0400

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year
Full data to be presented at upcoming scientific congress